 Oligonucleotides, Antisense
"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
| Descriptor ID |
D016376
|
| MeSH Number(s) |
D13.150.480 D13.444.600.150.640 D13.695.578.424.480 D27.720.470.530.600.150.640
|
| Concept/Terms |
Oligonucleotides, Antisense- Oligonucleotides, Antisense
- Antisense Oligonucleotides
- Anti-Sense Oligonucleotides
- Anti Sense Oligonucleotides
- Oligonucleotides, Anti-Sense
|
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".
This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in this website by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 1 | 1 | 2 | | 1997 | 2 | 2 | 4 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 6 | 7 | | 2004 | 2 | 6 | 8 | | 2005 | 0 | 3 | 3 | | 2006 | 1 | 2 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 1 | 4 | 5 | | 2009 | 2 | 2 | 4 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 4 | 4 | | 2012 | 0 | 1 | 1 | | 2014 | 4 | 1 | 5 | | 2015 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 3 | 4 | | 2022 | 0 | 2 | 2 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.
-
Paul S, Caruthers MH. Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry. Molecules. 2023 Jul 13; 28(14).
-
Lightbourne M, Startzell M, Bruce KD, Brite B, Muniyappa R, Skarulis M, Shamburek R, Gharib AM, Ouwerkerk R, Walter M, Eckel RH, Brown RJ. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. J Clin Lipidol. 2022 Nov-Dec; 16(6):850-862.
-
Le BT, Paul S, Jastrzebska K, Langer H, Caruthers MH, Veedu RN. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing. Proc Natl Acad Sci U S A. 2022 09 06; 119(36):e2207956119.
-
Li Y, Li J, Wang J, Lynch DR, Shen X, Corey DR, Parekh D, Bhat B, Woo C, Cherry JJ, Napierala JS, Napierala M. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 2021 11 18; 49(20):11560-11574.
-
Carvill GL, Matheny T, Hesselberth J, Demarest S. Haploinsufficiency, Dominant Negative, and Gain-of-Function Mechanisms in Epilepsy: Matching Therapeutic Approach to the Pathophysiology. Neurotherapeutics. 2021 07; 18(3):1500-1514.
-
Isom LL, Knupp KG. Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy. Neurotherapeutics. 2021 07; 18(3):1524-1534.
-
Eller KA, Aunins TR, Courtney CM, Campos JK, Otoupal PB, Erickson KE, Madinger NE, Chatterjee A. Facile accelerated specific therapeutic (FAST) platform develops antisense?therapies to counter multidrug-resistant bacteria. Commun Biol. 2021 03 12; 4(1):331.
-
Biayna J, Mazuelas H, Gel B, Terribas E, Dumbovic G, Rosas I, Fern?ndez-Rodriguez J, Blanco I, Castellanos E, Carri? M, Lazaro C, Serra E. Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation. Sci Rep. 2021 02 11; 11(1):3661.
-
Aunins TR, Erickson KE, Chatterjee A. Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CRE Escherichia coli. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30699-30709.
-
Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, Phan A, Bickett T, Jordan K, Proia T, Schulick R, Messersmith WA, Del Chiaro M, Clambey E, Gough MJ, Williams J, Hansen K, Goodman K, Karam SD. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol Immunother. 2021 Apr; 70(4):989-1000.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|